SenzaGen AB - Asset Resilience Ratio
SenzaGen AB (SENZA) has an Asset Resilience Ratio of 29.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is SenzaGen AB's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how SenzaGen AB's Asset Resilience Ratio has changed over time. See SENZA equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down SenzaGen AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SenzaGen AB market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr29.27 Million | 29.75% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr29.27 Million | 29.75% |
Asset Resilience Insights
- Very High Liquidity: SenzaGen AB maintains exceptional liquid asset reserves at 29.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
SenzaGen AB Industry Peers by Asset Resilience Ratio
Compare SenzaGen AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for SenzaGen AB (2016–2024)
The table below shows the annual Asset Resilience Ratio data for SenzaGen AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 35.39% | Skr39.61 Million ≈ $4.26 Million |
Skr111.91 Million ≈ $12.04 Million |
+17.26pp |
| 2023-12-31 | 18.14% | Skr17.62 Million ≈ $1.90 Million |
Skr97.18 Million ≈ $10.46 Million |
-15.19pp |
| 2022-12-31 | 33.33% | Skr39.98 Million ≈ $4.30 Million |
Skr119.95 Million ≈ $12.91 Million |
-18.36pp |
| 2021-12-31 | 51.69% | Skr69.16 Million ≈ $7.44 Million |
Skr133.81 Million ≈ $14.40 Million |
-28.40pp |
| 2020-12-31 | 80.09% | Skr89.34 Million ≈ $9.61 Million |
Skr111.55 Million ≈ $12.00 Million |
-4.17pp |
| 2019-12-31 | 84.27% | Skr120.47 Million ≈ $12.96 Million |
Skr142.96 Million ≈ $15.38 Million |
+21.87pp |
| 2018-12-31 | 62.39% | Skr56.45 Million ≈ $6.07 Million |
Skr90.47 Million ≈ $9.74 Million |
-13.51pp |
| 2017-12-31 | 75.90% | Skr82.48 Million ≈ $8.88 Million |
Skr108.67 Million ≈ $11.70 Million |
+11.25pp |
| 2016-12-31 | 64.65% | Skr22.58 Million ≈ $2.43 Million |
Skr34.92 Million ≈ $3.76 Million |
-- |
About SenzaGen AB
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices;… Read more